ABSTRACT Introduction: Antimicrobial resistance is an increasing threat in hospitalized patients, and inappropriate empirical antimicrobial therapy is known to adversely affect outcomes in ventilator-associated pneumonia (VAP). The aim of this study was to evaluate antimicrobial usage, incidence, etiology, and antimicrobial resistance trends for prominent nosocomial pathogens causing ventilatorassociated pneumonia in a clinical-surgical intensive care unit (ICU). Methods: Gram-negative bacilli and Staphylococcus aureus causing VAP, as well as their antimicrobial resistance patterns and data on consumption (defined daily dose [DDD] per 1,000 patient days) of glycopeptides, extended-spectrum cephalosporins, and carbapenems in the unit were evaluated in two different periods (A and B). Results: Antimicrobial use was high, mainly of broad-spectrum cephalosporins, with a significant increase in the consumption of glycopeptides (p < 0.0001) and carbapenems (p < 0.007) in period B. For Acinetobacter baumannii and members of the Enterobacteriaceae family, 5.27-and 3.06-fold increases in VAPs, respectively, were noted, and a significant increase in resistance rates was found for imipenem-resistant A. baumannii (p = 0.003) and third-generation cephalosporinsresistant Enterobacteriaceae (p = 0.01) isolates in this same period. Conclusions: Our results suggest that there is a link between antibiotics usage at institutional levels and resistant bacteria. The use of carbapenems was related to the high rate of resistance in A. baumannii and therefore a high consumption of imipenem/meropenem could play a major role in selective pressure exerted by antibiotics in A. baumannii strains.
INTRODUCTION
Ventilator-associated pneumonia (VAP) is the most-frequent intensive care unit (ICU)-acquired infection, occurring in 9.0-24% of patients intubated for longer than 48h. It is associated with increased morbidity, prolonged hospitalization, and increased healthcare costs 1 .
Antimicrobial resistance is an increasing threat in hospitalized patients, and both mortality and morbidity from infection are greater when caused by antimicrobial-resistant bacteria 2, 3 . Among these resistant bacteria, extended-spectrum cephalosporinresistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and ciprofloxacinresistant Enterobacteriaceae and non-fermentative Gram-negative bacilli (NFGNB) are of great concern because antimicrobial therapy for infections due to these resistant pathogens remains a clinical dilemma 2, 4 . Increases in the prevalence of these resistant pathogens are frequently related to the high selective pressure of antimicrobials commonly used in hospitalized patients, particularly extended-spectrum cephalosporins, β-lactam+β-lactamase inhibitor combinations, carbapenems, fluoroquinolones, and aminoglycosides 2, 5 .
Inappropriate empirical antimicrobial therapy is known to adversely affect outcome in pneumonia associated with a mechanical ventilator 6 and needs to be tailored to the institution's microbial ecology and the length of time the patient was in the hospital before pneumonia developed 4 . This question is frequent in Brazilian ICUs 7 . Multidrug-resistant organisms are far higher in ICUs in Latin America, Asia, Africa, and Europe than in U.S. ICUs 8 .
This report aims to evaluate antimicrobial usage, incidence, etiology, and antimicrobial resistance trends for prominent nosocomial pathogens causing ventilator-associated pneumonia in a clinical-surgical ICU in a Brazilian university hospital.
METHODS

Hospital and study design
This work was performed at the Uberlândia Federal University Hospital Clinic (HC-UFU) which is a teaching hospital with 500 beds and a clinical-surgical ICU of adults with 15 beds.
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RESULTS
Definition of hospital ventilator-associated pneumonia
The patients were under a mechanical ventilator for a period ≥ 48h after being admitted to the ICU, with new and/or progressive radiological infiltrate, and at least under two of the following criteria: purulent sputum, temperature higher than 38. .
Antibiotic consumption
Data on antibiotic consumption were evaluated in period A and May 2009 to August 2010 and were expressed as the number of defined daily doses (DDDs)/1,000 patients-day (pd) for the main classes of antibiotics used in our ICU: glycopeptides (vancomycin and teicoplanin), carbapenems (imipenem, meropenem, and ertapenem), and extendedspectrum cephalosporins (ceftriaxone and cefepime).
There were no interventions or changes in the antimicrobial use policy in the institution between the two periods.
Trends in resistance
To determine the trend of resistance in major Gram-negative pathogens and S. aureus causing VAPs in ICU patients in the HC-UFU, data on the disk diffusion susceptibilities of these organisms were interpreted according to Clinical and Laboratory Standards Institute (CLSI) criteria 10 , by the diameter of inhibition halo formed, using the following antimicrobial discs (Oxoid LTD., England): oxacillin (1ug), penicillin (10mg), erythromycin (15mg),
Etiology of ventilator-associated pneumonias
Periods A and B incidence density of major Gram-negative bacilli and S. aureus causing VAPs are shown in Table 1 and Figures 1 and 2 . For A. baumannii and members of the Enterobacteriaceae family, 5.27-and 3.06-fold increases in VAPs were nocted, respectively. On the other hand, there was a 2.0-fold decrease in the incidence density of S. aureus causing VAPs. Among the Gram-negative bacilli isolates, trends of increase in incidence density were significant (p ≤ 0.05) just among A. baumannii and members of the Enterobacteriaceae family causing VAPs ( Table 1) . Other non-fermenters, except P. aeruginosa and A. baumannii, were observed only in period B (1.62 isolates/1,000 patient-days).
cefoxitin (30mg), clindamycin (2mg), rifampicin (5mg), chloramphenicol (30mg), vancomycin (30mg), ciprofloxacin (5mg), gentamicin (10mg), cefepime (30mg), tetracycline (30mg) and sulphazotrim (25mg) for Gram-positive; imipenem (10mg), ciprofloxacin (5mg), ceftriaxone (30mg), gentamicin (10mg), piperacillin-tazobactam (100/10mg), polymyxin B (300u), cefepime (30mg), aztreonan (30mg), sulphazotrim (25mg) and tetracycline (30mg) for Gram-negative.
Statistical analysis
Analysis was performed by the Mann-Whitney test or Student T test after checking normality (Shapiro-Wilk and Lilliefors) and independence of the variables for comparisons between periods A and B.
Pearson's correlation coefficient was used to determine the relationship between antibiotic consumption and trends in resistance.
The results were considered statistically significant at a level of 5%. The epidemiological data were analyzed through the program Bioestat 5.0 11 .
Ethical considerations
The Ethics Committee for Human Research of the Uberlândia Federal University (UFU) approved the project under number 364/08. Period antibiotic consumption Table 2 shows the consumption of three classes of antibiotics in both periods. There was no significant variation in the consumption of broad-spectrum cephalosporins as opposed to glycopeptides (1.88-fold) and carbapenems (1.43-fold) when comparing periods A and B ( Table 2, Figures 1 and 2) .
In period A, the density of use of third-or fourth-generation cephalosporins grew in respect to glycopeptides and carbapenems (Table 2) . In period B, the consumption of antimicrobials was higher than in period A for all classes evaluated, with emphasis on higher-density use of broad-spectrum cephalosporins (Table 2) .
Relationship between antibiotic consumption and resistance
The overall rates of resistance to imipenem were 25% and 80.9% in A. baumannii and 62.5% and 45.5% in P. aeruginosa in periods A and B, respectively. For S. aureus, overall rates of resistance to oxacillin were 56.5% and 17.4% in periods A and B, respectively. Regarding third-generation cephalosporins, the overall rates of resistance were 20% and 56.7% in Enterobacteriaceae isolates in periods A and B, respectively. Table 1 shows the trends of resistance among Gram-negative pathogens and S. aureus.
In period A, only the consumption of carbapenems showed a significant correlation (Pearson r = 0.66/p=0.02) with the occurrence of VAPs by P. aeruginosa, especially with strains resistant to imipenem (Pearson r=0 .70/p=0.01) (Figure 3) . The rates of antibiotic resistance of other organisms were not correlated with the consumption of antimicrobials evaluated in the Pearson correlation test.
A significant increase in resistance rates in period B was found for imipenem-resistant A. baumannii and third-generation cephalosporinsresistant Enterobacteriaceae isolates. This same period showed a significant increase in consumption of carbapenems, and the use of broad-spectrum cephalosporins was still higher than during period A, but there was no correlation with resistance rates of these microorganisms in the Pearson correlation test. Figures 1 and 2 show the relationship between consumption of antibiotics and the etiology of VAPs. Regarding the etiology of VAPs, we observed a decrease in the frequency in VAPs caused by S. aureus and an increase in the frequency of VAPs by Gram-negative bacilli in period B. Changes in the frequency of these pathogens may be due to multiple factors (e.g., implementation of targeted surveillance, multidrug-resistant organism outbreaks, active surveillance, etc.) besides the agents may fluctuate over time 12 . Several studies found that prior administration of antibiotics can alter the distribution of microbial pathogens isolated from patients with VAP. For example, in a prospective study of 129 episodes of VAP, prior use of antibiotics significantly decreased the incidence of VAP caused by Gram-positive cocci or Haemophilus influenzae but increased the rate of those caused by P. aeruginosa 13 . In our ICU, we observed a decrease in rates of oxacillin-resistant Staphylococcus aureus (ORSA) despite the highest use of glycopeptides for empirical antimicrobial treatment of infections in the period B (p < 0.0001). In the UK hospitals, the introduction of mandatory surveillance and the use of a national clean your hands campaign resulted in a 50% reduction of ORSA bacteraemia 14 . In U.S. hospitals, ORSA central line-associated bloodstream infections (BSI) incidence also declined 50% or more in recent years in all major adult ICU types, as reported by the Centers for Disease Control and Prevention (CDC) 15 . These observations are consistent with reports of successful prevention efforts by health care teams that implemented programs designed to improve care practices 15 . Such decreases have been evident in other developed countries with national health care-associated infection surveillance and prevention efforts [15] [16] [17] .
The incidence of VAP due to major Gram-negative bacteria increased over time, but P. aeruginosa remained the most-prevalent bacteria, 40% and 32.4% in periods A and B, respectively, as represented in other South American ICUs 18 . In our study, 62.5% and 45.5% of P. aeruginosa isolates were resistant to imipenem in periods A and B, respectively. These rates are high when compared with those in other studies 8, 19 .
Acinetobacter baumannii is another important cause of nosocomial infections in many hospitals, which is difficult to both control and treat because of its prolonged environmental survival and its ability to develop resistance to multiple antimicrobial agents 20, 21 . A. baumannii pneumonia occurs predominantly in selected subjects with various risk factors such as mechanical ventilator, residence in an ICU, and prior antibiotic use mainly of broad-spectrum drugs such as thirdgeneration cephalosporins and carbapenems 22 . In our study, A. baumannii rates increased in period B (p = 0.008), and this bacteria was the second-most-frequently isolated in this period when the use of broad-spectrum cephalosporins and carbapenems were higher than in period A (p = 0.33 and 0.007, respectively) and extremely high when compared to rates of use in U.S. 23 generation cephalosporins, respectively). A. baumannii appears to have a propensity for developing antimicrobial resistance extremely rapidly. Moreover, this resistance is multiple, causing serious therapeutic problems 20 . Carbapenems are usually the antibiotics of choice for treating serious infections caused by this microorganism. However, reports of imipenem-resistant A. baumannii strains have been rising steadily during the past few year, and these isolates are often multidrug-resistant 20, 21, 24 . Although these multiresistant A. baumannii strains may still retain susceptibility to polymyxins (i.e., colistin and polymyxin B), sulbactam and possibly tigecycline pan-resistant isolates that are resistant to all available drugs are now reported 24 . In our study, 25% and 80.9% of the isolates of A. baumannii were resistant to carbapenems in periods A and B, respectively (p = 0.003).
Gram-negative bacilli of the Enterobacteriaceae family are common causes of health-care-associated pneumonias 25 . Emerging resistance in this microorganism is a significant problem that requires immediate attention, and the increasing prevalence of multidrug-resistance Enterobacteriaceae challenges the use of third-generation cephalosporins for empirical treatment of nosocomial infections 25, 26 . In our study, the rates of Enterobacteriaceae isolates increased in period B (p = 0.02) and were the third-most-isolated pathogen during this period; 20.0% and 56.7% of these microorganisms were resistant to third-generation cephalosporins in periods A and B, respectively (p = 0.01). The emergence of extendedspectrum β-lactamases (ESBLs) necessitated the increased use of carbapenems, but this increased use of drugs of last resort may be contributing to the emergence of multidrug-resistant non-fermentative Gram-negative bacilli 27, 28 .
The root causes of the rapid emergence and dissemination of drug-resistant bacteria in hospitals are multifactorial 2, 29, 30 , including mainly the high selective pressure that results from inappropriate and widespread use of antimicrobial agents particularly in ICUs; cross transmission from patient to patient owing to inconsistent application of appropriate infection control measures; clonal spreading of resistant bacteria and horizontal transfer of resistance genes; and a complex relationship between resistance and use of a variety of antimicrobials 2, 29, 31 . However, increasing resistance may further drive increased consumption of several so-called last-line antimicrobial agents 2 . In this study, the increase in the incidence of VAP due to multidrug-resistant A. baumannii and third-generation cephalosporins-resistant Enterobacteriaceae resulted in an increase of carbapenems. The increased use of these agents was associated with an increase in the incidence of VAPs due to carbapenem-resistant A. baumannii.
Our results suggest a link between antibiotics usage at institutional levels and resistant bacteria. The emergence of P. aeruginosa in our ICU necessitated the increased use of carbapenems, which may contribute to the emergence of multidrug-resistant non-fermentative Gram-negative bacilli, mainly A. baumannii. Antibiotic resistance is an inevitable consequence of inappropriate antibiotic use, which is more likely in units with high prevalence of multidrug-resistant microorganisms.
DISCUSSION
